Literature DB >> 1355735

Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors.

P Maguire1, N Tsai, J Kamal, C Cometta-Morini, C Upton, G Loew.   

Abstract

Receptor binding assays using [3H]DAGO ([D-Ala2,MePhe4-Gly5-ol]enkephalin) (mu), [3H]DPDPE ([D-Pen2,D-Pen5]enkephalin) (delta) and [3H]U-69593 (kappa) were done in guinea pig whole brain membranes. Agonist activity was determined in norbinaltorphimine or beta-funaltrexamine (beta-FNA) treated guinea pig ileum (mu and kappa, respectively) and beta-FNA-treated mouse vas deferens (delta). The compounds with highest affinity were the most potent at the mu-receptor. The selectivity observed in the binding affinities was also found in in vitro activity. No correlation was found between mu-affinity and selectivity; the highest affinity analog, lofentanil, was found to be among the least selective, while another high affinity analog, R30490, was the most mu-selective. The results show that not all fentanyls are highly mu-selective, and could produce actions through delta- and kappa-opiate receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355735     DOI: 10.1016/0014-2999(92)90685-w

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  39 in total

1.  A new method for evaluating sigma(2) ligand activity in the isolated guinea-pig bladder.

Authors:  Nicola A Colabufo; Francesco Berardi; Marialessandra Contino; Roberto Perrone; Vincenzo Tortorella
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-17       Impact factor: 3.000

2.  Case Series: Rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users.

Authors:  John J Mariani; Amy Mahony; Muhammad N Iqbal; Sean X Luo; Nasir H Naqvi; Frances R Levin
Journal:  Am J Addict       Date:  2020-03-13

Review 3.  Pharmacotherapy of opioids: present and future developments.

Authors:  T F Meert
Journal:  Pharm World Sci       Date:  1996-01

4.  Development of a common 3D pharmacophore for delta-opioid recognition from peptides and non-peptides using a novel computer program.

Authors:  P Huang; S Kim; G Loew
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

5.  Mapping neurotransmitter networks with PET: an example on serotonin and opioid systems.

Authors:  Lauri Tuominen; Lauri Nummenmaa; Liisa Keltikangas-Järvinen; Olli Raitakari; Jarmo Hietala
Journal:  Hum Brain Mapp       Date:  2013-05-14       Impact factor: 5.038

Review 6.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

7.  'Carba'-carfentanil (trans isomer): a μ opioid receptor (MOR) partial agonist with a distinct binding mode.

Authors:  Grazyna Weltrowska; Carole Lemieux; Nga N Chung; Jason J Guo; Brian C Wilkes; Peter W Schiller
Journal:  Bioorg Med Chem       Date:  2014-07-29       Impact factor: 3.641

8.  Designing traceable opioid material§ kits to improve laboratory testing during the U.S. opioid overdose crisis.

Authors:  Mike A Mojica; Melissa D Carter; Samantha L Isenberg; James L Pirkle; Elizabeth I Hamelin; Rebecca L Shaner; Craig Seymour; Cody I Sheppard; Grant T Baldwin; Rudolph C Johnson
Journal:  Toxicol Lett       Date:  2019-09-24       Impact factor: 4.372

9.  The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.

Authors:  Ling Jong; Nurulain Zaveri; Lawrence Toll
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

Review 10.  Fentanyl for the treatment of tumor-related breakthrough pain.

Authors:  Helmar Bornemann-Cimenti; Mischa Wejbora; Istvan S Szilagyi; Andreas Sandner-Kiesling
Journal:  Dtsch Arztebl Int       Date:  2013-04-19       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.